Eisai Co., Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EII.F | SH0.F | 2186.HK | NBIX | 2096.HK | ALVO | |
|---|---|---|---|---|---|---|
| Market cap | 7.90B | 13.83B | 6.77B | 14.40B | 27.83B | 1.85B |
| P/E (TTM) | 35.9 | 9.4 | 21.2 | 20.8 | 16.0 | — |
| Forward P/E | 23.7 | 5.2 | 6.3 | 11.8 | 11.8 | 22.6 |
| Price/book | 1.5 | 1.4 | 0.4 | 3.9 | 2.5 | -9.7 |
| Dividend yield | 3.27% | 2.64% | — | — | 1.89% | — |
| 1-year change | +7.13% | +21.60% | −47.99% | +0.37% | −14.73% | −37.79% |
| Today | +1.82% | +2.01% | +0.59% | −0.27% | −0.64% | +1.37% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All EII.F news ›Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026
TradingView Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026 TOKYO, Oct 16, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across…
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi
China's National Medical Products Administration approved Eisai and Biogen's subcutaneous autoinjector version of anti-amyloid beta protofibril antibody Leqembi as an initiation treatment for... Eisai, Biogen Secure China's Nod for…
Eisai And Biogen Receive Approval For Leqembi Subcutaneous Formulation As Initiation Treatment For Early Alzheimer's Disease In China
Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration of China has approved the subcutaneous formulation , the anti-amyloid beta protofibril antibody LEQEMBI ...
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.